Results of GSK and AstraZeneca trials may widen ovarian cancer drug use

GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.


from Reuters: Health News https://ift.tt/2nmOMv4

Comentarii

Postări populare de pe acest blog

Telehealth hubs offer care options for people living on the edge the virtual world

Overuse on cattle feedlots is a key factor in antibiotic resistance, report says

Bringing Your Ballpark Food Favorites Home